All In Biotech

Free tool

FAERS Monitor: Trelegy Ellipta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209482 or its brand name (Trelegy Ellipta, Fluticasone Furoate, Umeclidinium Bromide, Vilanterol Trifenatate). Reports on generic versions are filed under their own applications.

Reports

43,081

Serious

17,505

41% of reports

Hospitalization

8,710

Death reported

3,373

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea6,025
  • drug ineffective3,674
  • product dose omission issue3,485
  • wrong technique in device usage process3,401
  • product complaint3,063
  • cough3,012
  • death2,401
  • pneumonia2,203
  • asthma1,886
  • chronic obstructive pulmonary disease1,648
  • fatigue1,468
  • off label use1,436
  • product use in unapproved indication1,422
  • headache1,420
  • dysphonia1,190

Reports by year received

View as table
YearReports
20151
20166
201721
20181,227
20193,883
20203,782
20214,331
20224,768
20235,640
20246,970
20257,120
20265,332

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,011,078 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product complaintSignal3,06367.064.6175,208
wrong technique in device usage processSignal3,40138.337.0114,648
chronic obstructive pulmonary diseaseSignal1,64815.915.122,309
dysphoniaSignal1,19010.19.69,597
asthmaSignal1,8868.37.911,907
product dose omission issueSignal3,4855.85.714,016
coughSignal3,0125.35.110,501
dyspnoeaSignal6,0255.25.121,020
pneumoniaSignal2,2033.33.23,637
product use in unapproved indicationSignal1,4222.82.71,668
drug ineffective3,6741.41.3376
death2,4011.41.3239
headache1,4201.11.115
fatigue1,4680.90.910
off label use1,4360.80.874

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.